Living Cell Technologies Ltd. (AU:1AI)
ASX:1AI
Want to see AU:1AI full AI Analyst Report?
1AI Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume31.97M
Average Volume (3M)2.98M
Market Cap
AU$22.28M
Enterprise ValueAU$17.71M
Total Cash (Recent Filing)AU$1.88M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)22.0
Beta0.15
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,025,571,000
10 Day Avg. Volume1,972,597
30 Day Avg. Volume2,982,772
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially lowers ongoing financing costs and insolvency risk, giving management more runway to progress clinical programs without interest pressure. This structural strength preserves optionality for partnerships or equity raises over the next several months.
Improving Loss TrajectoryA material narrowing of net losses signals improving operating efficiency or cost control versus prior years. If sustained, this trend lengthens cash runway, reduces the size/frequency of future funding needs, and improves credibility with partners and investors over a 2-6 month horizon.
Specialized Clinical-stage TechnologyA focused R&D platform in encapsulated cell therapies is a high-barrier, differentiated asset base. Clinical-stage programs create durable strategic optionality—licensing, partnerships, or milestone payments—supporting long-term value creation if trials progress positively.
Bears Say
Effectively No RevenueA structural absence of commercial revenue means the company cannot internally fund development or operations. Long-term viability therefore hinges on external financing or successful asset monetisation, increasing dilution and execution risk over coming months.
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates steady cash burn despite recent improvement. This structural outflow erodes reserves, forces recurring fundraising, and constrains the company's ability to invest or respond to setbacks without dilutive or costly financing.
Eroding Equity And Shrinking AssetsDeclining equity and materially lower assets reflect cumulative losses and reduced balance-sheet flexibility. This shrinkage impairs the company's capacity to absorb trial delays or fund operations, raising medium-term financing and operational risk.
Living Cell Technologies News
1AI FAQ
What was Living Cell Technologies Ltd.’s price range in the past 12 months?
Living Cell Technologies Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Living Cell Technologies Ltd.’s market cap?
Living Cell Technologies Ltd.’s market cap is AU$22.28M.
When is Living Cell Technologies Ltd.’s upcoming earnings report date?
Living Cell Technologies Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 61 days.
How were Living Cell Technologies Ltd.’s earnings last quarter?
Living Cell Technologies Ltd. released its earnings results on Feb 27, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Living Cell Technologies Ltd. overvalued?
According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued.
Does Living Cell Technologies Ltd. pay dividends?
Living Cell Technologies Ltd. does not currently pay dividends.
What is Living Cell Technologies Ltd.’s EPS estimate?
Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Living Cell Technologies Ltd. have?
Living Cell Technologies Ltd. has 2,025,571,000 shares outstanding.
What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?
Living Cell Technologies Ltd. reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:1AI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Living Cell Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:1AI Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-49.25%
Trailing 12-Months
Asset Growth
-15.04%
Trailing 12-Months
Company Description
Living Cell Technologies Ltd.
Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.
Technical Analysis
Cynata Therapeutics Limited
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Options Prices
Currently, No data available
---